Leerink Partners analyst Puneet Souda maintained a Buy rating on Repligen (NASDAQ:RGEN) Corp on Tuesday, setting a price target of $260, which is approximately 14.85% above the present share price of $226.38.
Souda expects Repligen Corp to post earnings per share (EPS) of $0.54 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Repligen, with an average price target of $258.33.
The analysts price targets range from a high of $275 to a low of $240.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $142.84 million and a net profit of $36.38 million. The company's market cap is $12.43 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.9% and a 60.43% success rate.
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.